Loading...
Loading...
Browse all stories on DeepNewz
VisitWill Finch Therapeutics' stock price remain above $5 by the end of 2024?
Yes • 50%
No • 50%
Stock price data from major financial news platforms such as Yahoo Finance or Bloomberg
Finch Therapeutics Secures $25M Judgment, 5.5% Royalties on ITD Rebyota Sales
Aug 9, 2024, 08:46 PM
Finch Therapeutics Group, Inc. ($FNCH), a microcap company, has been awarded a legal judgment totaling $25 million, along with an additional $800,000 in royalties, representing 5.5% of ITD Rebyota sales, following a patent-related court case. The judgment is expected to significantly impact the company's financial standing, as it previously had a market capitalization of just $6 million and approximately $15 million in cash. The legal outcome has led to a substantial increase in the company's stock price, which has surged by approximately 350% since June 2. The awarded damages and royalties are likely to provide a financial cushion for Finch Therapeutics, potentially alleviating concerns about its cash burn rate. The company's stock was trading at less than $1 prior to the judgment, reflecting the transformative effect of the legal victory on its market valuation.
View original story
Below $2 • 25%
$2 to $5 • 25%
Above $10 • 25%
Below $5 • 25%
$5 to $10 • 25%
$10 to $15 • 25%
Above $15 • 25%
Significantly outperform • 25%
Slightly outperform • 25%
Match sector performance • 25%
Underperform • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 50% • 25%
More than 200% • 25%
100% to 200% • 25%
50% to 100% • 25%
$1 million to $5 million • 25%
Below $1 million • 25%
$5 million to $10 million • 25%
Above $10 million • 25%